Avadel Pharmaceuticals (AVDL): Market Cap to Earnings and Growth Ratio

Symbol and logo of brand Avadel Corp (AVDL)

Avadel Pharmaceuticals (AVDL) bases its strategy on independently launching its product into the US market without mergers. The history of PEG ratio changes confirms this trajectory, where the value of 0.00 expresses the metric level. Profitability relies on the launch of Lumryz, prescription volume, and insurance coverage. The unique once-daily dosing format provides the company with exceptional pricing power.

Avadel Pharmaceuticals (AVDL): Price/Earnings to Growth Multiple from 07/04/2022 to 02/28/2026

Analytical breakdowns for Avadel Pharmaceuticals (AVDL)

- share price and consensus valuation forecast:
Price Performance Chart Avadel Pharmaceuticals PLC|AVDL - Price Target Chart
- stock exchange capitalization data:
Market Valuation Avadel Pharma|AVDL - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Share Avadel Pharmaceuticals|AVDL - Company Net Assets|Market-to-Book Ratio avadel.com|AVDL - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Avadel Pharmaceuticals|AVDL - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital avadel.com|AVDL - Company Debts|Debts to Book Value Avadel Pharma|AVDL - Company Long-Term Debts|Company Short-Term Debts Avadel Pharmaceuticals|Quick Liquidity avadel.com
- net income and valuation ratios data:
AVDL - Net Profit|Projected Future Earnings Avadel Pharmaceuticals|AVDL - P/E Multiple|Price to Future Earnings Ratio Avadel Corp|AVDL - PEG Multiple|Company Value to EBITDA Avadel Pharma|AVDL - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Avadel Pharmaceuticals|AVDL - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months avadel.com|AVDL - Earnings per share growth in current year|Net earnings per share change forecast for next year Avadel Pharmaceuticals
Fundamental company analysis:AVDL - Avadel Pharmaceuticals PLC
Original product of avadel.com

To minimize risks when selecting an issuer, it is necessary to compare market value with the pace of business expansion. The PEG ratio is calculated as the P/E ratio divided by the annual earnings growth rate, and a PEG value below one indicates an undervaluation of Avadel Pharmaceuticals (AVDL), whose stability in the US domestic market could only be impacted by disruptions in Asian raw material supplies.

Competing companies

ALKS (Alkermes PLC) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio atai Life Sciences Corp ATAI|GHRS (GH Research Group) - Market Cap to Earnings and Growth Ratio|MNMD - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income compasspathways.com CMPS|LBRX (LB Pharmaceuticals) - Price/Earnings to Growth Multiple|Price to Earnings Adjusted for Growth Rate Bright Minds Bio (DRUG)|VNDA (Vanda Pharmaceuticals Inc) - PEG Multiple|Price/Earnings to Growth Multiple Cybin Corp (CYBN)|PEG Multiple ANRO|NRXP (nrxpharma.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Cingulate CING|silopharma.com (SILO) - Price to Earnings Adjusted for Growth Rate|China Pharma - PEG Multiple|CMND - PEG Multiple|PBM (Psyence Biomedical Ltd.) - Price/Earnings to Growth Multiple|SPRC (scisparc.com) - Price/Earnings to Growth Ratio|SEEL (Seelos Therapeutics, Inc.) - PEG Multiple|PEG Multiple Virpax|PEG Multiple KRTX